GlaxoSmithKline同意为80,000 Zantac的癌症索赔诉讼提出2.2B的解决方案。 GlaxoSmithKline agrees to a $2.2B settlement for 80,000 Zantac lawsuits over cancer claims.

GlaxoSmithKline(GSK)已同意一项22亿美元的解决方案,以解决美国大约80,000起与其心脏灼伤药物Zantac有关的诉讼,原告声称Zantac造成癌症。 GlaxoSmithKline (GSK) has agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits in the U.S. related to its heartburn drug Zantac, which plaintiffs claim caused cancer. 这一解决办法处理93%的待决案件,不涉及承认责任。 This settlement addresses 93% of pending cases and does not involve an admission of liability. GSK称,没有可靠的证据证明Zantac与癌症风险有关。 GSK asserts there is no reliable evidence linking Zantac to cancer risk. 该公司预计到2025年年中完成结算。 The company anticipates completing the settlement by mid-2025.